Some of the most promising new medicines—gene-silencing siRNAs, antisense oligonucleotides, and CRISPR-based therapies—are failing in late-stage clinical trials because they damage the liver, kidneys, or immune system in ways researchers do not fully understand. This partnership between the MRC Toxicology Unit, AstraZeneca, and other labs aims to fix that. The core problem is that current animal and cell models cannot reliably predict which of these nucleic-acid-based drugs will trigger dangerous side effects, and the underlying biological pathways that lead to toxicity remain poorly characterised. Without this knowledge, drug developers cannot design safer versions or screen out harmful candidates early. If successful, the project will produce three concrete outputs: new lab assays that flag toxic compounds before they reach patients, advanced humanised tissue models that mimic kidney toxicity more accurately than animal tests, and machine-learning algorithms that predict which chemical sequences are likely to be safe. These tools will be made openly available to the wider biomedical community through the Mary Lyon Centre and public repositories. The work also aims to inform new regulatory guidelines from the MHRA, EMA, and FDA, potentially reshaping how these therapies are tested and approved.
View original technical description
Programmable nucleic acid-dependant therapies (NADTs) including siRNAs, antisense oligonucleotides (ASOs), CRISPR-cas 9 based editing systems, and modified in vitro transcribed mRNAs have the potential to transform healthcare. There have been considerable successes in NADT development, including the FDA/MHRA approved therapies Givosiran (siRNA) for acute hepatic porphyria and Nusinersen (ASO) for spinal muscular atrophy. However there have also been notable failures such as the ASOs Tominersin for Huntington’s Disease treatment and SRP-5051-201 for Duchenne’s Muscular Dystrophy. The emerging clinical toxicities which have resulted in withdrawal of NADTs from phase II/III clinical trials are hepato-, renal- and immuno-toxicity. There are 3 major factors which contribute to the general failures of NATDs namely, an incomplete understanding of mechanisms of toxicity associated with the on- and off-target binding of NADTs, insufficient predictability of preclinical cell/animal models and an inability to predict which chemistries/sequences trigger adverse outcome pathways (AOPs). The ability to address these challenges requires a broad range of expertise and multidisciplinary partnership between academia and industry. This proposed partnership between the MRC Toxicology Unit (MRC-TU/UoC), Astra Zeneca (AZ), Mary Lyon Centre (MLC) and CRUK Scotland Institute (CRUK-SI) brings together individuals with unique skill sets and our combined efforts, working closely in the precompetitive space, will provide solutions to these major challenges. We will investigate ASOs, siRNAs and CRISPR-based editing systems. The nucleic acids that form a key part of these therapies and the AOPs that they trigger are conserved and by studying these 3 modalities we will gain essential information about the commonalities and distinctions of on- and off-target toxicities of NADTs. Four work-packages are proposed where the combined outputs will improve the safety profiles of NADTs. WP1: We will gain mechanistic understanding of the toxicities associated with NADTs, identify ways in which to improve their safety profiles, and generate new assays that predict adverse outcome. WP2: To develop novel, advanced humanised preclinical models to predict NADT toxicity in vitro. We will develop an advanced humanised model that is able to recapitulate kidney toxicity, since trial failure is frequently due to renal toxicity. WP3: To generate algorithms that are predictive of toxic NADTs to inform the safe-by-design agenda. To achieve this aim we will use multi-omic data sets provided by AZ in parallel with machine learning and AI. WP4: Translation of research outputs for stakeholder benefit. In this WP, the assays/tools (WP1) and the advanced humanised models (WP2) will be made available through the MLC which will run assays and screens, accessible and affordable to the wider biomedical community. The algorithms that predict safe ASO design (WP3) will be made available through open-access repositories. We will collaborate with regulatory bodies (MHRA, EMA, FDA) and contribute to new regulatory guidelines. Our approaches will be informed by clinical data obtained from patient cohorts, and interaction with patient interest groups, via UpNAT. Finally, the training provided in the partnership will build a diverse workforce with capacity and capability in safety science, ensuring the UK has a world-leading position in the development of advanced therapeutics for socioeconomic benefit.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know